Optimizing Glioma Detection Using an EGFR-Targeted Fluorescent Affibody.

Area of Science:

• Oncology
• Molecular Imaging
• Pharmacokinetics

Background:

• Epidermal Growth Factor Receptor (EGFR) is overexpressed in many cancers, making it a target for diagnosis and therapy.
• EGFR-targeted fluorescent Affibody (ABY-029) shows potential for glioma detection.
• Understanding uptake kinetics is crucial for optimizing tumor detection efficacy.

Purpose of the Study:

• To investigate the uptake kinetics of ABY-029 for glioma detection.
• To evaluate the impact of ABY-029 dose and cetuximab administration on tumor-to-normal brain contrast.
• To determine the optimal dosage for effective glioma detection using ABY-029.

Main Methods:

• U251 glioma cells were implanted in nude rats.
• Fluorescence imaging of rat brains after ABY-029 administration.
• Ex vivo imaging to analyze tumor-to-normal brain ratios at varying ABY-029 doses and with/without cetuximab.

Main Results:

• Cetuximab blocked ABY-029 binding to EGFR in cell culture but did not affect tumor-to-normal brain contrast in vivo.
• Ex vivo imaging demonstrated increased tumor-to-normal brain ratios with higher ABY-029 doses.
• A saturation value was reached at 245 μg kg⁻¹, a 10-fold increase over the microdose.

Conclusions:

• Glioma detection is optimized when ABY-029 dosage surpasses the FDA-defined microdose.
• The dose of ABY-029 is a critical factor for effective tumor visualization.
• Concurrent cetuximab administration did not enhance tumor contrast in this model.